Targeting C5a or the C5aR might thus be a viable solution for modulating NET formation in RA, thus preventing the destruction of cartilage (Carmona-Rivera et al., 2020) and bone (O'Neil et al., 2020) and reducing endothelial cell damage (Schreiber et al., 2017). This evidence concerns the gene C5 and rheumatoid arthritis.